Abstract
RON (Receptuer dOrigine Nantaise) is a member of the MET receptor tyrosine kinase family. RON is expressed in various cell types including macrophages, epithelial and hematopoietic cells. Its ligand, macrophage stimulating protein (MSP, also known as hepatocyte growth factor-like protein), is a multifunctional factor regulating cell growth and survival, adhesion and motility, cytokine production and phagocytosis. Accumulated data indicate that in addition to the regulation of normal cell functions, RON can be involved in cancer development and progression: (i) RON is overexpressed and constitutively active in some primary tumors and tumor cell lines, (ii) experimental mutations of RON cause oncogenic cell transformation, and (iii) RON mediates susceptibility to Friend-virus-induced erythroleukemia in mice. Constitutive activation of intracellular signaling pathways such as the PI-3 kinase / AKT, beta-catenin, MAPK and JNK pathways may underlie the molecular mechanism of RON-mediated oncogenic cell transformation. The present review describes RON-activated signaling pathways, which may play an important role in tumor formation and metastasis.
Keywords: oncogenic signaling, ron, met receptor, ron receptor tyrosine kinase
Current Cancer Drug Targets
Title: Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase
Volume: 3 Issue: 1
Author(s): Alla Danilkovitch-Miagkova
Affiliation:
Keywords: oncogenic signaling, ron, met receptor, ron receptor tyrosine kinase
Abstract: RON (Receptuer dOrigine Nantaise) is a member of the MET receptor tyrosine kinase family. RON is expressed in various cell types including macrophages, epithelial and hematopoietic cells. Its ligand, macrophage stimulating protein (MSP, also known as hepatocyte growth factor-like protein), is a multifunctional factor regulating cell growth and survival, adhesion and motility, cytokine production and phagocytosis. Accumulated data indicate that in addition to the regulation of normal cell functions, RON can be involved in cancer development and progression: (i) RON is overexpressed and constitutively active in some primary tumors and tumor cell lines, (ii) experimental mutations of RON cause oncogenic cell transformation, and (iii) RON mediates susceptibility to Friend-virus-induced erythroleukemia in mice. Constitutive activation of intracellular signaling pathways such as the PI-3 kinase / AKT, beta-catenin, MAPK and JNK pathways may underlie the molecular mechanism of RON-mediated oncogenic cell transformation. The present review describes RON-activated signaling pathways, which may play an important role in tumor formation and metastasis.
Export Options
About this article
Cite this article as:
Danilkovitch-Miagkova Alla, Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase, Current Cancer Drug Targets 2003; 3 (1) . https://dx.doi.org/10.2174/1568009033333745
DOI https://dx.doi.org/10.2174/1568009033333745 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fungal Proteins with Antiproliferative and Anticancer Activities
Protein & Peptide Letters The Role of Nucleoside Transport in the Antineoplastic Activity of Purine Nucleoside Chemotherapeutic Agents
Current Cancer Therapy Reviews Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway
Current Topics in Medicinal Chemistry Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design
Current Topics in Medicinal Chemistry The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Current Neuropharmacology Chemosensitization by Antisense Oligonucleotides Targeting MDM2
Current Cancer Drug Targets Higher Placental Anti-Inflammatory IL-10 Cytokine Expression in HIV-1 Infected Women Receiving Longer Zidovudine Prophylaxis Associated with Nevirapine
Current HIV Research Activin Receptor-Like Kinases: Structure, Function and Clinical Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Functionalization for Maximizing Cell Turnover from Microcarrier
Current Biotechnology Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design Phosphonomethoxyalkyl Analogs of Nucleotides
Current Pharmaceutical Design Enzyme / Abzyme Prodrug Activation Systems: Potential Use in Clinical Oncology
Current Pharmaceutical Design Current Status and Future Perspective for Research on Medicinal Plants with Anticancerous Activity and Minimum Cytotoxic Value
Current Drug Targets Effects of Limonoid Cedrelone on MDA-MB-231 Breast Tumor Cells in vitro
Anti-Cancer Agents in Medicinal Chemistry Role of the Renin-Angiotensin System in Gynecologic Cancers
Current Cancer Drug Targets